Peptide appearance
Lyophilized form helps protect peptide quality. Peptides are supplied as a dry powder, which may look like a compact "puck" or a lighter powder inside the vial.
Because the peptide is dry, it does not require refrigerated shipping during normal transit, including warm seasonal conditions. For longer storage, follow the storage guidance in the product description.
Appearance can vary. The stated peptide content is checked through third-party analysis.
Read more in the product description.
Solution not bundled
Peptides are delivered as lyophilized powder. This dry form helps preserve peptide quality during storage and transport and does not require refrigerated shipping during normal transit.
To prepare a solution, use a solvent such as Bacteriostatic water. It is sold separately, so add it only when you need it for peptide preparation.
Read more in the product description.
GHRH analogue
CJC-1295 with DAC
In stock
CJC-1295 with DAC is a synthetic GHRH analogue with a drug-affinity-complex modification. Published studies look at albumin binding, longer circulation, and endocrine signals.
Order within — · ships today Cutoff 10:00 · local time
Arrives Sep 24 - Sep 28 to Europe
More at checkout
CJC-1295 with DAC
88,90 €
DAC-linked GHRH analogue for albumin-binding and extended-exposure pathway studies.
Research overview
CJC-1295 with DAC
The DAC modification makes this analogue different from modified GRF(1-29) without DAC. This difference matters when comparing binding, duration, and receptor-signalling studies.
Studies measure growth-hormone release, growth-related markers, and reproductive-system signals. These are study findings, not claims about the supplied material.
Albumin binding and signalling duration
The DAC group is designed to bind albumin and extend circulation in laboratory models. Researchers compare how this changes exposure and endocrine measurements versus a no-DAC analogue.
Each comparison should use the exact sequence, assay, and observation time reported in the paper.
Endocrine model endpoints
Published studies also measure growth-hormone and IGF-related endpoints. These measurements do not define the quality or behaviour of a supplied lot.
Compound information
Specifications
Molecular profile
- Sequence
- Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(N-epsilon-maleimidopropionyl)-NH2
- Molecular mass
- 3647.2 g/mol
- CAS number
- 446262-90-4
- Molecular formula
- C165H269N47O46
Material record
- Physical appearance
- White to off-white lyophilized powder
- Solubility
- Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
- Product note
- Albumin-binding GHRH analogue research compound; supplied strictly for research use only.
Laboratory care
Handling
Peptides in transport
Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.
Storage of lyophilized peptides
Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Up to 3 months
- Refrigerated (2–8 °C): Up to 6 months
- Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)
Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.
Storage of reconstituted peptides
Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.
The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Avoid prolonged storage
- Refrigerated (2–8 °C): Typically 4–8 weeks
- Frozen (-20 °C or below): Up to 3–4 months
To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.
Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.
Analytical documentation
Latest test results
Latest published result
Liquilabs s.r.o.Signed Certificate of Analysis · 5 mg
98.6%Purity by HPLC
Recorded QC panel
- AssayPeptide Screening 0.1% TFA
- 4.10 mg (± 0.02 mg)
- PurityPeptide Screening 0.1% TFA
- 98.6%
- Identity (FTIR)Peptide Screening 0.1% TFA
- 980 (± 5)
- Identity (RT)Retention time
- 0.997 (± 0.005)
- Bacterial endotoxinUSP 85 / Eur. Ph. 2.6.14
- Less than 0.001 EU/mg
These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.
Source record
References
National Center for Biotechnology Information
PubChem Compound Summary: CJC-1295
Authoritative identity record for CJC-1295 with DAC.
PubChem · View source ↗Teichman SL, Neale A, Lawrence B, et al. · 2006
Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults
Primary characterisation of CJC-1295 as a long-acting GHRH analogue.
Journal of Clinical Endocrinology and Metabolism · 10.1210/jc.2005-1536 View source ↗Sackmann-Sala L, Ding J, Frohman LA, et al. · 2009
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
Primary CJC-1295 study reporting serum-protein profiling.
Growth Hormone and IGF Research · 10.1016/j.ghir.2009.03.001 View source ↗M. Ionescu and L. A. Frohman · 2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
J. Clin. Endocrinol. Metab ·· 2005
Sam L. Teichman et al., „Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults, 91(3):799-805, Epub 2005 Dec 13
·M. Alba et al. · 2006
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
Am. J. Physiol. Endocrinol. Metab ·A. Volpe, G. Coukos, A. Barreca, G. Giordano, P. G. Artini, and A. R. Genazzani · 1991
Clinical use of growth hormone-releasing factor for induction of superovulation
Hum. Reprod ·Customer reviews
Continue exploring
